- TOPHAT
Trial of Ondansetron as a Parkinson’s Hallucinations Treatment
Open to new recruits: Yes
Study Drug: Ondansetron/Placebo
Inclusion criteria:>18yo, PD diagnosis, experiencing visual hallucinations
Participating Scottish sites: Dundee, Aberdeen & Glasgow
- RAPSODI GD
Remote assessment of Parkinsonism supporting ongoing development of interventions in Gaucher disease
Open to new recruits: Yes
Study Drug: No
Inclusion criteria: Anyone with a diagnosis of Parkinson’s Disease
Participating Scottish sites: Dundee
Website: https://www.parkinsons.org.uk/research/pd-frontline-identifying-genes-people-parkinsons
- ABBVIE M15-741 & M15-737
Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion
Open to new recruits: No
Study Drug: Yes: 24hour sub-cutaneous levodopa/carbidopa infusion pump
Inclusion criteria: >30yo, idiopathic PD that is levodopa-responsive
Participating Scottish sites: Dundee
Website: https://clinicaltrials.gov/ct2/show/NCT04379050
- ROPAD III
Rostock International Parkinson’s Disease Study Program: An International, Multicentre, Epidemiological Observational study
Open to new recruits: Yes
Study Drug: No
Inclusion criteria: >18yo, PD diagnosis or family member of participant with LRRK2 parkinsonism/member of high risk population
Participating Scottish sites: Dundee
- LIPAD
LRRK2/Luebeck International Parkinson's Disease Study Protocol: Deep Phenotyping of an International Genetic Cohort
Open to new recruits: Yes
Study Drug: No
Inclusion criteria: Involved in the ROPAD study. Parkinson’s diagnosis. Healthy volunteer.
Participating Scottish sites: Dundee
- CHIEF-PD
Cholinesterase Inhibitor to prevent falls in Parkinson’s Disease: A phase 3 randomised, double-blind placebo-controlled trial of Rivastigmine to prevent falls in Parkinson’s
Open to new recruits: No
Study Drug: Rivastigmine/Placebo
Inclusion criteria: >18yo, PD diagnosis, experienced falls, able to walk without assistance
Participating Scottish sites: Dundee, Edinburgh, Aberdeen
Website: https://chiefpd.blogs.bristol.ac.uk/
- PADOVA
A Phase IIB, randomized, double-blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of intravenous Prasinezumab.
Open to new recruits: No
Study Drug: Prasinezumab/placebo
Inclusion criteria: >50-85yo, PD diagnosis 6M-3yr at screening, 3m stable treatment
Participating Scottish sites? Dundee
- LUMA and LIGHTHOUSE
The Luminare Studies are evaluating the safety and efficacy of a study drug, as compared to a placebo, to see if it may delay the progression of Parkinson’s disease in people who are in the early stage of their condition. The Luminare Studies include 2 individual studies, LUMA and LIGHTHOUSE. They are both evaluating the same study drug but each study has different criteria to participate.
Open to new recruits: Yes
Study Drug: BIIB122/placebo
Inclusion criteria: LUMA. 30-80 years old. Diagnosed with Parkinson’s disease within the last 2 years and were at least 30 years old when you were diagnosed.
LIGHTHOUSE: 30-80 years old. Diagnosed with Parkinson’s disease within the last 5 years and were at least 30 years old when you were diagnosed. Have genetic testing results showing that you have specific mutations in the LRRK2 gene (genetic testing provided by the study site).
Participating Scottish sites: Dundee
- EPSILON
A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel-Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add-on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inhibitor (DDCI) Therapy in Early Idiopathic Parkinson's Disease Patients, With an Open-Label Extension
Open to new recruits: No
Study Drug: Opicapone/placebo
Inclusion criteria: Age 30-80, diagnosis of PD within last 5 years
Participating Scottish sites: Dundee
- Neuroprogressive and Dementia Network website: https://www.nhsresearchscotland.org.uk/research-areas/dementia-and-neurodegenerative-disease
- For further information of other research studies: https://bepartofresearch.nihr.ac.uk/